For research use only. Not for therapeutic Use.
RR-RJW100, the enantiomer of RJW100, is an nuclear receptor liver receptor homolog 1 (LRH-1) and steroidogenic factor 1 (SF-1) agonist. RJW100 can be synthesized as two enantiomers, RR-RJW100 and SS-RJW100, with RR-RJW100 shown to be the more potent LRH-1 agonist. RR-RJW100 is involved in the regulation of metabolic homeostasis and is used in studies of diabetes, liver disease and inflammatory bowel disease[1][2].
| Catalog Number | I042847 |
| Synonyms | (1R,3aR,6aR)-5-hexyl-4-phenyl-3a-(1-phenylethenyl)-2,3,6,6a-tetrahydro-1H-pentalen-1-ol |
| Molecular Formula | C28H34O |
| Purity | ≥95% |
| InChI | InChI=1S/C28H34O/c1-3-4-5-8-17-24-20-25-26(29)18-19-28(25,21(2)22-13-9-6-10-14-22)27(24)23-15-11-7-12-16-23/h6-7,9-16,25-26,29H,2-5,8,17-20H2,1H3/t25-,26+,28-/m0/s1 |
| InChIKey | ZFXMYHPLTQTTFW-REUBFRLUSA-N |
| SMILES | CCCCCCC1=C(C2(CCC(C2C1)O)C(=C)C3=CC=CC=C3)C4=CC=CC=C4 |
| Reference | [1]. Suzanne G Mays, et al. Enantiomer-specific activities of an LRH-1 and SF-1 dual agonist. Sci Rep. 2020 Dec 17;10(1):22279. [2]. Alisa Lang, et al. The Medicinal Chemistry and Therapeutic Potential of LRH-1 Modulators. J Med Chem. 2021 Dec 9;64(23):16956-16973. |
